Hospital Universitario Fundación Jiménez Díaz- START MADRID

Madrid 28040

2 studies enrolling now · 4 studies all time

What they study most

Advanced Cancer, B-cell Malignancies, Cholangiocarcinoma, Chronic Lymphocytic Leukemia, FGFR2 Amplification, FGFR2 Gene Activation, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Mutation, FGFR2 Gene Translocation, Head and Neck Cancer, Intrahepatic Cholangiocarcinoma, Lung Cancer

Studies at this site

• A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement — Recruiting now
• A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies — Recruiting now
• REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors — Completed
• Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors — Status unconfirmed